Kymera Therapeutics, Inc. Net Income Loss

Quick Answer

Kymera Therapeutics, Inc. reported Net Income Loss of -$311.35 million for the year ending 2025.

  • Kymera Therapeutics, Inc. showed a decrease of -39.1% in Net Income Loss from 2024 to 2025.
  • This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Kymera Therapeutics, Inc.'s Net Income Loss has declined by 654.9%.
  • Historical annual values: Fiscal year 2025: -$311.35 million | Fiscal year 2024: -$223.86 million | Fiscal year 2023: -$146.96 million | Fiscal year 2022: -$154.81 million | Fiscal year 2021: -$100.22 million | Fiscal year 2020: -$45.59 million | Fiscal year 2019: -$41.25 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: